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Abstract
Asthma is a chronic inflammatory respiratory disease that affects over 300 million people worldwide. Glucocorticoids are a
mainstay therapy for asthma because they exert anti-inflammatory effects in multiple lung tissues, including the airway
smooth muscle (ASM). However, the mechanism by which glucocorticoids suppress inflammation in ASM remains poorly
understood. Using RNA-Seq, a high-throughput sequencing method, we characterized transcriptomic changes in four
primary human ASM cell lines that were treated with dexamethasone—a potent synthetic glucocorticoid (1 mM for
18 hours). Based on a Benjamini-Hochberg corrected p-value ,0.05, we identified 316 differentially expressed genes,
including both well known (DUSP1, KLF15, PER1, TSC22D3) and less investigated (C7, CCDC69, CRISPLD2) glucocorticoid-
responsive genes. CRISPLD2, which encodes a secreted protein previously implicated in lung development and endotoxin
regulation, was found to have SNPs that were moderately associated with inhaled corticosteroid resistance and
bronchodilator response among asthma patients in two previously conducted genome-wide association studies.
Quantitative RT-PCR and Western blotting showed that dexamethasone treatment significantly increased CRISPLD2 mRNA
and protein expression in ASM cells. CRISPLD2 expression was also induced by the inflammatory cytokine IL1b, and small
interfering RNA-mediated knockdown of CRISPLD2 further increased IL1b-induced expression of IL6 and IL8. Our findings
offer a comprehensive view of the effect of a glucocorticoid on the ASM transcriptome and identify CRISPLD2 as an asthma
pharmacogenetics candidate gene that regulates anti-inflammatory effects of glucocorticoids in the ASM.
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Introduction
Asthma, a chronic inflammatory respiratory disease that affects
over 25 million Americans and 300 million people world-wide, is
characterized by variable airflow limitation and airway hyperre-
sponsiveness [1,2]. Glucocorticoids (GCs) are common medica-
tions used to treat various inflammatory diseases, including asthma
[3]. Inhaled corticosteroids, GC medications that act directly in
the lung, are among the most common asthma controller
medications and treatment of asthma patients with them leads to
improved clinical outcomes, including decreased asthma symp-
toms and exacerbations [4]. At a cellular level, GCs act by binding
to GC receptors (GRs), causing them to translocate to cell nuclei
where they modulate transcription of various genes in a tissue-
dependent fashion [5]. The anti-inflammatory action of GCs is
partly a result of 1) GC-GR complexes stimulating anti-
inflammatory genes by directly binding to DNA at glucocorticoid
receptor enhancer elements, and of 2) GC-GR complexes
inhibiting proinflammatory transcription factors such as nuclear
factor kappa-light-chain-enhancer of activated B cells (NFkB) [6].
In addition to directly reducing inflammation, GCs have been
shown to affect other asthma-related phenotypes, including
bronchodilation [7], airway hyperresponsiveness [8], and airway
smooth muscle (ASM) contractility [9].
Many cells and tissues are involved in asthma and are targeted
by GCs, including inflammatory [10,11], airway epithelium [12],
and ASM [13]. Of these, the ASM is involved in altered airway
contractility [14], a major asthma-specific trait that is assessed
clinically and for research studies by measures such as broncho-
dilator response [15] and airway hyperresponsiveness [16].
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e99625However, compared to the other airway cells, much less is known
about how GCs work specifically in the ASM to alleviate asthma.
Because GCs function by activating GR to directly modulate
transcriptional gene expression, a better understanding of how the
ASM transcriptome responds to GCs is needed to provide
mechanistic insights for improving asthma therapy. Several studies
have been conducted to identify GCs-induced transcript changes
in the ASM. For example, two microarray-based gene expression
studies have measured the effect of GCs on ASM cells using in vitro
models where human ASM cells were stimulated with dexameth-
asone or fluticasone [17,18]. Although both were limited by the
inherent biases of microarrays, these studies identified some genes
involved in the ASM GC response, with one focusing on validating
the function of the KLF15 gene in airway hyperresponsiveness [17]
and the other on the overlap between GC and beta-agonist
response of the ASM [18].
Recent advances in sequencing technologies have made possible
the comprehensive and in-depth characterization of transcrip-
tomes via a technique known as RNA-Seq [19–21]. Compared to
the use of microarrays, RNA-Seq is able to (1) quantify more RNA
species, including non-coding and novel splice variants, (2)
quantify RNA at baseline, rather than only measure fold changes
across conditions, and (3) cover a wider dynamic range of signal
[22]. In this study, we used RNA-Seq to comprehensively
characterize changes of the ASM transcriptome in response to
GCs using an in vitro model. We identified 316 significantly
differentially expressed genes representing various functional
categories such as glycoprotein/extracellular matrix, vasculature
and lung development, regulation of cell migration, and extracel-
lular matrix organization. One of these genes, cysteine-rich
secretory protein LCCL domain-containing, 2 (CRISPLD2;
OMIM 612434), had single nucleotide polymorphisms (SNPs)
that were nominally associated with two asthma drug response
phenotypes (i.e., inhaled corticosteroid response and short-acting
bronchodilator response). Functional experiments showed that in
ASM cells, CRISPLD2 mRNA and protein levels changed in
response to treatment with a glucocorticoid or proinflammatory
cytokine, and that knockdown of CRISPLD2 resulted in increased
levels of IL1b-induced IL6 and IL8 mRNA expression.
Results
RNA-Seq Transcriptome Profiling of GC-treated Primary
Human ASM Cells
To identify GC-responsive genes in ASM, we performed RNA-
Seq expression profiling of primary ASM cells from four white
male donors treated with 1 mM dexamethasone (DEX) or control
vehicle for 18 h, a treatment protocol that captures a large set of
genes regulated by the GR [17]. We obtained an average of 58.9
million raw sequencing reads per sample (range 44.2–71.3 million
reads per sample). Of these reads, an average of 83.36% were
aligned to hg19 genome reference files downloaded from
Illumina’s iGenomes project (range 81.94%–84.34%) [Table
S1]. An average of 26.43% of the mapped reads spanned
junctions. Most bases in mapped reads corresponded to mRNA
(.98%) [Table S2]. Plots of normalized read coverage of
transcripts vs. normalized position, reveals that there was even
coverage of transcripts by reads [Figure S1]. Based on these and
various quality control (QC) summary metrics, including ERCC
spike-in dose response plots, the sequencing and alignment results
for each sample were deemed of sufficiently high quality to include
in differential expression analyses. Quantification of transcript and
gene expression levels was performed using Cufflinks according to
hg19 RefSeq annotation files from Illumina’s iGenomes Project.
Overall, 316 genes were significantly differentially expressed
after correcting for false discovery rate by the Benjamini-
Hochberg [23] approach [Figure 1A, Table S3]. Table 1 contains
the genes with Q-value ,1E-10 that were considered for further
study. Some of these top genes have been previously related to
steroid responsiveness and inflammation (i.e., DUSP1 [24], FKBP5
[25], KLF15 [17], PER1 [12,26], and TSC22D3 [25,27]), and their
upregulation by 1 mM for 18 DEX was confirmed by quantitative
real time PCR (qRT-PCR) in ASM cells from three donors
[Figure 1B]. qRT-PCR results for the fourth donor used in the
RNA-Seq experiment were also consistent [Figure S2]. Other
genes identified via the RNA-Seq experiment were considered
potentially novel GC-responsive genes as they have little published
evidence regarding a relationship with steroid responsiveness and/
or inflammation. Gene set enrichment analysis using the NIH
DAVID tool [28] identified various Gene Ontology and other
annotation categories that were overrepresented by the 316 genes.
The top six gene functional annotation clusters (enrichment scores
.3) had terms related to: glycoprotein/extracellular matrix,
vasculature development, circulatory system process, response to
nutrients, thrombospondin type-1, and response to hormone
stimulus terms [Table S4]. Other clusters among the 19 with
enrichment scores .1.5 that may be relevant to lung disease
included lung development, regulation of cell migration, and
extracellular matrix organization.
Verification of GC-responsive Genes by q-PCR
A subset of the top differentially expressed genes (i.e.,
CRISPLD2, C13orf15, KCTD12, SERPINA3) was selected for
follow-up based on each gene’s potential to be a novel steroid
responsiveness gene. Differential expression for these four genes
and one additional gene selected from the top 316 differentially
expressed ones (i.e., PTX3) was verified via qRT-PCR by treating
with 1 mM DEX for 18 h three of the ASM cell lines used for
RNA-Seq [Figure 2] to compare biological sample variability and
effect sizes obtained via RNA-Seq vs. qRT-PCR. qRT-PCR
results for the fourth donor were consistent with those for the other
three cell lines [Figure S2]. Gene expression levels varied among
the primary cell lines, suggesting an inherent heterogeneity in
individual GC responsiveness. Nevertheless, the qRT-PCR data
for each of the genes was consistent in direction of fold-change
with the RNA-Seq results.
CRISPLD2 Variants Associated with Asthma
Pharmacogenetic Phenotypes
Inhaled corticosteroid (ICS) responsiveness is a measure of
improvement in pulmonary function after treatment with a
glucocorticoid. To determine whether any of the differentially
expressed genes were associated with this pharmacogenetic
phenotype, defined as unchanged improvement in lung function
among asthma patients after receiving ICS therapy for 4–8 weeks,
we obtained previously conducted ICS GWAS results (unpub-
lished) for SNPs within, or spanning 50 kb on either side, each of
the genes in Table 1. Based on a threshold of 1E-03, the
CRISPLD2 gene had SNPs that were nominally associated with
ICS resistance [Table 2; Figure S3]. Because the beta-agonist and
glucocorticoid pathways are known to overlap [29], we also
examined the association of the differentially expressed genes with
bronchodilator response, which measures the effect of beta-
agonists on lung function. Based on bronchodilator response
GWAS results from a previous study where the phenotype was
defined as change in FEV1 in response to administration of the
beta-agonist albuterol [30], SNPs in CRISPLD2 and an additional
gene CCDC69 were nominally associated with the bronchodilator
CRISPLD2 Is a Glucocorticoid Responsive Gene in ASM
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one SNP (rs8047416) from this bronchodilator response GWAS
that had a primary P-value of 4.5E-04 had been obtained for 552
white subjects from the Severe Asthma Research Program (SARP)
cohort and found to have a P-value of 0.038 (overall P-value 9.0E-
05). Together these results suggest a role for CRISPLD2 in
modulating two asthma pharmacogenetic phenotypes.
CRISPLD2 Expression Changes in Previous Microarray
Studies of the ASM GC Response
We analyzed publicly available data from two published gene
expression microarray studies (GSE34313 [17] and GSE13168
[18]) that measured the effect of GCs on human ASM cells to
determine whether these previous studies supported our
CRISPLD2 differential expression results. Although CRISPLD2
did not rank as one of the most highly differentially expressed
genes in these studies, all comparisons available between ASM
cells treated with a GC vs. baseline conditions demonstrate that
CRISPLD2 had significant adjusted P-values [Table 3]. Specifical-
ly, the GSE34313 study found that CRISPLD2 was differentially
expressed both 4 and 24 hours after ASM cells were treated with
DEX, and the GSE13168 study found that the differential
CRISPLD2 expression was strongest when ASM cells were treated
with a GC (i.e. fluticasone) vs. left untreated, than when cells were
also stimulated with pro-inflammatory cytokines (i.e. EGF and
IL1b).
GC Induced CRISPLD2 mRNA and Protein Expression in
Primary Human ASM Cells
Because of its potential to modulate two important asthma drug
response phenotypes vis-a `-vis these associations and published
evidence of its involvement in lung development and endotoxin
Figure 1. RNA-Seq profiling of DEX-treated ASM cells. A) Volcano plot of overall gene-based differential expression results for four cell lines
treated with DEX vs. left untreated (each dot corresponds to a gene). The y-axis corresponds to the negative log (base 10) of P-values while the x-axis
corresponds to the negative log (base 2) of the fold change for difference in expression when cells were stimulated with DEX. There were 316
differentially expressed genes according to an adjusted p-value ,0.05 (blue dots). B) Validation of known GC-responsive genes through qRT-PCR.
After ASM cells were treated with 1 mM DEX for 18 h, the mRNA levels of indicated genes were measured by qRT-PCR and the folds of change in
mRNA induced by DEX were calculated. Each column bar represents an individual cell line. Experiments for each cell line were performed in triplicate,
and the error bars are SE values corresponding to a cell line’s replicates. The dotted line indicates a fold change of 1. ** P,0.005, * P,0.05 (t test).
doi:10.1371/journal.pone.0099625.g001
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CRISPLD2 gene to investigate its potential role in steroid and
immune response in ASM cells. We grew the most GC sensitive
ASM cell line among those tested in Figure 2, treated those cells
with DEX, and extracted RNA for qRT-PCR and protein for
immune-blot analysis. Upon DEX treatment, CRISPLD2 mRNA
increased 8.1-fold [Figure 3A]. Consistent with mRNA changes,
protein levels of CRISPLD2 in ASM cells also increased upon DEX
treatment by 1.7-fold at 24 hours [Figure 3B]. Using cells from a
single donor, the effect of DEX on CRISPLD2 expression was
found to be time [Figure S4A] and dose dependent [Figure S4B].
The induction of CRISPLD2 by DEX that was observed in ASM
did not occur in A549 pulmonary epithelial cells derived from a
lung carcinoma tissue, as analogous treatment of A549 cells with
DEX caused a decrease of CRISPLD2 mRNA [Figure S5].
CRISPLD2 is Induced by IL1b and Modulates the
Expression of Two Immuno-Responsive Genes
Because GCs exert anti-inflammatory effects, we tested the role
of GC-induced CRISPLD2 expression in regulating inflammatory
responses in the ASM. Treatment of a single ASM cell line with
Table 1. Top (Q-value ,1E-10) differentially expressed genes.
Gene locus
Mean FPKM
Control Mean FPKM Dex Ln[ Fold Change ] P-value Q-value
C7 chr5:40909598-40983042 3.76 38.41 3.35 ,1E-16 ,1E-16
CCDC69 chr5:150560612-150603654 6.24 47.39 2.92 ,1E-16 ,1E-16
DUSP1 chr5:172195092-172198203 18.26 144.96 2.99 ,1E-16 ,1E-16
FKBP5 chr6:35541361-35704724 3.43 53.05 3.95 ,1E-16 ,1E-16
GPX3 chr5:150399998-150408554 45.18 613.37 3.76 ,1E-16 ,1E-16
KLF15 chr3:126061477-126076236 0.86 20.46 4.58 ,1E-16 ,1E-16
MAOA chrX:43515408-43606068 4.41 43.24 3.29 ,1E-16 ,1E-16
SAMHD1 chr20:35504569-35580246 17.27 245.78 3.83 ,1E-16 ,1E-16
SERPINA3 chr14:95078713-95090390 13.78 139.89 3.34 ,1E-16 ,1E-16
SPARCL1 chr4:88394487-88450655 1.07 27.88 4.70 ,1E-16 ,1E-16
C13orf15 chr13:42031541-42045013 10.00 96.35 3.27 2.2E-16 2.5E-13
TSC22D3 chrX:106956451-107019017 9.69 93.26 3.27 2.2E-16 2.5E-13
CRISPLD2 chr16:84853586-84943116 7.89 51.17 2.70 6.7E-16 6.9E-13
PER1 chr17:8043787-8055753 1.49 13.69 3.20 3.8E-15 3.6E-12
KCTD12 chr13:77454303-77460540 31.25 5.43 -2.52 1.2E-14 1.1E-11
ERRFI1 chr1:8071778-8086393 13.48 72.70 2.43 1.3E-13 1.1E-10
STEAP4 chr7:87905743-87936228 0.20 6.35 4.99 6.7E-13 5.3E-10
FPKM = fragments per kilobase of transcript per million mapped reads.
doi:10.1371/journal.pone.0099625.t001
Figure 2. Validation of GC responsive genes. After cells from three individual ASM lines were treated with 1 mM DEX for 18 h, the mRNA levels
of indicated genes were measured by qRT-PCR and the folds of change induced by DEX were calculated. Each column bar represents an individual
cell line; experiments for each cell line were performed in triplicate. Error bars are SE values corresponding to a cell line’s replicates.
doi:10.1371/journal.pone.0099625.g002
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CRISPLD2 mRNA by 10.4-fold and protein levels by 1.9-fold
[Figure 3C and 3D], suggesting that CRISPLD2 is not only GC-
inducible but also immuno-responsive. We next performed
knockdown experiments to assess whether CRISPLD2 modulates
IL1b-induced cytokine responses using a single ASM cell line.
Because IL1b acts as an important mediator of inflammatory
responses by activating other cytokines, we investigated the role of
CRISPLD2 in IL1b-induced expression of other known immune-
response genes (i.e. IL6 [32] and IL8 [33]). In ASM cells
transfected with CRISPLD2-specific siRNA, CRISPLD2 mRNA
expression was decreased by 74% and protein levels decreased by
60% [Figure 4A].
While expression levels of IL6 did not change in response to
CRISPLD2 knockdown, treatment of ASM cells with IL1b induced
significantly higher expression of IL6 in CRISPLD2-knockdown
cells as compared to NT siRNA control cells [Figure 4B],
suggesting that CRISPLD2 is an inhibitory modulator of immuno-
response in ASM cells. Consistent with this notion, another
cytokine’s (i.e. IL8’s) induction by IL1b was also enhanced by
CRISPLD2 knockdown [Figure S6]. To further characterize the
effect of CRISPLD2 on immune response, we treated cells with
100 nM DEX alone or in combination with 5 ng/mL IL1b. IL6
expression was decreased with DEX treatment, but CRISPLD2
knockdown did not significantly change the IL6 response to DEX
[Figure 4C]. However, IL6 mRNA levels in CRISPLD2 knock-
down cells were higher than that in NT siRNA control cells when
IL1b and DEX were administered simultaneously [Figure 4D],
again supporting a role for CRISPLD2 in modulating IL1b
response.
CRISPLD2 is Not Required for the Expression of GC Target
Genes
We performed siRNA-mediated CRISPLD2 knockdown exper-
iments to assess whether CRISPLD2 affects the transcriptional
expression of well-known GC-response genes (i.e. DUSP1 [24],
FKBP5 [25] or TSC22D3 [25,27]). The expression levels of three
GR target genes were not significantly altered in CRISPLD2-
knockdown ASM cells relative to control non-targeting siRNA-
transfected cells [Figure S7], suggesting that CRIPSLD2 does not
modulate the direct transcriptional actions of GCs in the ASM.
Discussion
Due to their widespread use in the treatment of various
inflammatory diseases and the notoriety of their undesirable side
effects, GCs have been extensively characterized for their effects
on specific tissues [3,34]. In the case of asthma, an important
target of GCs is the ASM [13]. Our RNA-Seq, qRT-PCR and
immuno-blot results demonstrated that CRISPLD2 is a GC
responsive gene, with DEX increasing its mRNA and protein
levels. We found that CRISPLD2 mRNA and protein levels
increase in response to treatment with a known pro-inflammatory
cytokine (IL1b), and that CRISPLD2 knockdown increased the
IL1b responsiveness of two inflammatory genes (i.e. IL6 and IL8),
suggesting that CRISPLD2 may regulate immune response.
Specifically, CRISPLD2 may interfere with IL1b-induced cytokine
production and act to reduce immune response via a negative
feedback loop that can be activated by IL1b. This negative
feedback loop may also play a role in cytokine level modulation in
response to DEX treatment, as evidenced by the increased levels of
IL6 observed when both IL1b and DEX were administered to
CRISPLD2 knockdown ASM cells vs. when DEX was administered
alone.
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PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e99625The CRISPLD2 gene maps to chromosome 16 at 16q24.1,
covering 118.32 kb. According to AceView [35], CRISPLD2 is
highly expressed in many human tissues, including lung and
trachea. While AceView describes 14 different mRNAs as
transcript products for this gene, only one of these (NM_031476)
was part of the RefSeq annotation file used in the RNA-Seq
analysis. Based on mapping of raw reads, each exon of this
reported mRNA isoform was expressed in our ASM samples
[Figure S8]. Results obtained after repeating the alignment and
transcript reconstruction with parameters that allow for the
discovery of novel isoforms while using the reference hg19 genome
as a guide, also suggested that a single CRISPLD2 mRNA isoform
(NM_031476) was present in the ASM samples. Further studies
are required to find out whether CRISPLD2 splicing variation
Table 3. Differential expression results for CRISPLD2 obtained from publicly available data of two previous microarray studies that
investigated the effects of GCs on human ASM cells.
Study Comparison Group Rank Adjusted P-value Fold Change
GSE34313 4 hr DEX vs. baseline 305 5.1E-05 1.85
GSE34313 24 hr DEX vs. baseline 850 8.3E-06 1.95
GSE13168 Fluticasone vs. basal 6 3.9E-07 6.09
GSE13168 Fluticasone+EGF vs. EGF 4 2.4E-05 4.33
GSE13168 Fluticasone+IL1b vs. IL1b 45 1.5E-03 2.78
GSE13168 Fluticasone+EGF+IL1b vs. EGF+IL1b 68 3.9E-02 2.13
Rank refers to ranking within all differentially expressed genes of each comparison group.
doi:10.1371/journal.pone.0099625.t003
Figure 3. CRISPLD2 is a GC- and IL1b-responsive gene. ASM cells were treated with 100 nM DEX for 24 h, resulting in A) increased CRISPLD2
mRNA expression as measured by qRT-PCR, B) increased CRISPLD2 protein expression as measured by immuno-blotting. ASM cells were treated with
5 ng/mL IL1b for 24 h, resulting in C) increased CRISPLD2 mRNA expression as measured by qRT-PCR, and D) increased CRISPLD2 protein expression
as measured by immuno-blotting. CRISPLD2 mRNA levels were measured in triplicate. CRISPLD2 protein levels are shown as normalized blot
densitometry values, and the error bars are SE values across three independent experiments. * P,0.05 (t test).
doi:10.1371/journal.pone.0099625.g003
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other biological conditions.
The cell-specific effects of GCs are well known [5] and
understanding the mechanisms of such specificity is an active
area of research [12,36]. For example, a study of the cell-specific
responsiveness of PTX3 to GCs found that in fibroblasts and
endothelial cells, the GR functioned as a ligand-dependent
transcription factor to induce PTX3 gene expression, while in
macrophages and myeloid dendritic cells, the GR repressed PTX3
transcription by interfering with the action of other signaling
pathways [37]. Comparison of baseline CRISPLD2 expression in
ASM vs. A549 pulmonary epithelial cells revealed that CRISPLD2
is more highly expressed in ASM [Figure S5A]. This finding is
consistent with the results from Reddy et al, who found low levels
of CRISPLD2 mRNA in A549 cells [12]. While ASM CRISPLD2
levels increased in response to DEX, levels decreased in A549 cells
according to our experiments [Figure S5B] and were not
significantly changed after 100 nM DEX treatment for 1 hour
in the Reddy et al [12] study. In a study using BEAS-2B cells,
CRISPLD2 expression was induced by both a glucocorticoid
(fluticasone) and a long-acting beta-agonist (formoterol) [38].
Further studies are required to understand the cell-specific
expression of CRISPLD2 and its interactions with other asthma
medications.
A hypothesis of the mechanism by which GCs activate
CRISPLD2 in ASM is provided by the chromatin immunoprecip-
itation followed by DNA sequencing (ChIP-Seq) results from
Reddy et al, who sought to identify regions of the genome where
GRs bind at various concentrations of DEX (100 nM 50 nM,
5 nM, 500 pM) [12]. Their results, which are part of the
Transcription Factor ChIP-Seq V4 results from ENCODE [39],
in/near CRISPLD2 indicate that a region between its transcription
start site (TSS) and first exon binds GRs [Figure S8]. While Reddy
et al did not further characterize the GR binding of CRISPLD2
because this gene was not DEX-responsive in their study, our
RNA-Seq results along with their ChIP-Seq results suggest that
GCs may activate CRISPLD2 in ASM by binding to GR enhancer
regions. However, future ChIP experiments are necessary to
validate the exact location and sequence of this potential GR-
binding site that may increase CRISPLD2 expression in ASM cells.
CCAAT/Enhancer Binding Proteins (CEBPs) are a family of
transcription factors that help regulate a wide variety of processes,
including inflammatory response [40]. Two of these factors,
CEBPB and CEBPD, have been shown to be induced by GCs in
lung epithelium [41] and skeletal muscle cells [42]. Additionally,
the transcription of CEBPB has been shown to be induced by IL1,
IL6, and lipopolysaccharide (LPS) [40]. ENCODE Transcription
Factor ChIP-Seq V4 results suggest that CEBPs may also induce
transcription of CRISPLD2 [Figure S8]. Specifically, two CEBPB
binding regions detected in untreated A549, HepG2 (hepatocel-
lular carcinoma), IMR90 (fetal lung fibroblasts), and K562
(immortalized chronic myelogenous leukemia) cells between the
Figure 4. CRISPLD2 regulates the response to inflammatory cytokines. A) Effect of CRISPLD2-specific siRNA on CRISPLD2 mRNA and protein
levels. ASM cells were transfected with CRISPLD2-specific siRNA or non-targeting (NT) siRNA, and 72 h later, CRISPLD2 mRNA and protein levels were
determined by qRT-PCR (levels normalized to those in control cells transfected with NT siRNA) and immuno-blotting, respectively. The effect of
CRISPLD2 knockdown on IL1b-induced cytokine expression was assessed by transfecting ASM cells with CRISPLD2-specific or NT siRNA, and 72 h later,
treating cells for 24 h with B) 5 ng/mL IL1b, C) 100 nM DEX, or D) 5 ng/mL IL1b and 100 nM DEX. IL6 expression was determined by qRT-PCR.
Normalized mRNA levels are shown. Experiments were performed in triplicate, and the error bars are SE values for three samples. * P,0.05 (t test).
doi:10.1371/journal.pone.0099625.g004
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scores of 1000 out of 1000 (all others near/in CRISPLD2 have
scores of ,435). According to our RNA-Seq data, both CEBPB
and CEBPD were expressed in ASM [Figure S9], but only CEBPD
had significantly increased mRNA levels in response to treatment
with DEX [Q-value 4.8E-04, Ln of fold-change 1.47]. Thus, if
DEX does indeed mediate changes in expression of CRISPLD2 in
the ASM via CEBPB binding, it likely does so via a post-
translational mechanism such as by changing phosphorylation
[43]. Future ChIP experiments are necessary to confirm that
CEBPB binding contributes to CRISPLD2 expression in ASM.
The potential presence of both GR and CEBPB binding sites in
CRISPLD2 is consistent with our observation that both DEX and
IL1b increased CRISPLD2 mRNA expression, findings that may
seem at odds because one mechanism by which GCs act is to
decrease expression of cytokines such as IL1b. Because IL1
induces CEBPB expression [44], IL1b may induce transcription of
CRISPLD2 via increased binding of CEBPB to a CEBPB
transcription factor in CRISPLD2 in the absence of a GC
[Figure 3C]. The control ASM cell lines used to obtain RNA-
Seq results expressed low levels of IL1b both at baseline (FPKM
=0.04) and when treated with DEX (FPKM =0.01), and thus, we
did not characterize the relationships among DEX, IL1b and
CRISPLD2 that would be expected of a disease involving high
levels of IL1b. Further studies examining changes of expression of
CRISPLD2 under varying concentrations of DEX and IL1bwould
help to clarify the relationships among them.
CRISPLD2 (a.k.a. Lgl1 in rat) has been identified as a
developmental gene that modulates branching morphogenesis in
fetal rat lung [45] and its variants have been related to non-
syndromic cleft lip with or without cleft palate in human
association studies [46]. In a recent study of CRISPLD2’s role
in endotoxin regulation, CRISPLD2 was found to bind to LPS,
thereby preventing LPS from binding target peripheral blood
mononuclear cells (PBMCs) and inhibiting the release of
proinflammatory markers (i.e. TNFa and IL6) by these target
cells [31]. Endogenous CRISPLD2 in healthy human serum was
found to downregulate LPS-induced TNFa production in vitro, and
CRISPLD2 was found to protect mice from endotoxic shock. A
subsequent study of CRISPLD2 found that its protein levels were
decreased in blood serum of patients with septic shock compared
to controls, patients with sepsis and patients with severe sepsis [47].
However, CRISPLD2 levels were not related to clinical outcomes
(e.g., survival). Although their use is highly controversial, GCs
have been used to treat septic shock [48], and thus, one area of
future study could be to characterize the relationships among GCs,
CRISPLD2 and LPS in septic shock. Our findings that CRISPLD2
knockdown increased IL6 and IL8 levels, while DEX increased
CRISPLD2 levels, taken together with the study by Wang, et al
demonstrating that CRISPLD2 plays a role in endotoxin
regulation, suggest that CRISPLD2, in part, may modulate
asthma phenotypes by decreasing the ASM inflammatory response
to exogenous LPS-containing bacteria. However, the role of LPS
and endotoxin in the development of asthma or its exacerbations is
not fully understood [49], and further studies are needed to test
potential roles of CRIPSLD2 in linking GCs and inflammation to
endotoxin regulation.
In addition to published evidence that CRISPLD2 may indirectly
play a role in asthma, SNPs of this gene were associated with two
asthma pharmacogenetic traits measured in asthma clinical trials.
Each of these traits was relevant to GC response and ASM
contractility: ICS resistance was a direct measure of treatment
with a glucocorticoid, while bronchodilator response was a
measure of beta-agonist effects, and the beta-agonist and
glucocorticoid pathways are known to overlap [29]. Interestingly,
the region of association with BDR overlaps with the GR and
CEBPB DNA-binding regions mentioned above [Figure S10]. In a
previous study, the long-acting beta-agonist formoterol was found
to activate a CEBP-luciferase reporter construct in BEAS-2B cells,
and mice with a lung epithelial-specific knockout of CEBPB were
found to have an impaired suppression of LPS-induced neutro-
philia by formoterol compared to control littermates [50]. Thus, it
is possible that this region of association with bronchodilator
response reflects a functional change that alters GR and/or
CEBPB binding, but further experiments are required to test this
hypothesis. While the nominal associations with ICS resistance
and bronchodilator response do not reach genome-wide signifi-
cance, and hence, would not suggest that CRISPLD2 variants be
prioritized for further study based on the GWAS data alone, in the
context of the current GC responsiveness results, they suggest that
specific regions in/near CRISPLD2 may modulate asthma
phenotypes in humans.
Results from two publicly available gene expression microarray
studies that have measured the effect of GCs on human ASM cells
using in vitro models supported our CRISPLD2 findings [Table 3].
The first study by Masuno, et al (GSE34313) investigated the
effects of DEX at 4 and 24 hours and focused on the functional
validation of the KLF15 gene, which was found to modulate airway
hyperresponsiveness, but not inflammatory response, in an
ovalbumin challenge mouse asthma model [17]. While not among
their top-ranked findings, CRISPLD2 expression was increased by
DEX at both 4 and 24 hours in the experiments by Masuno, et al.
Consistent with our findings, DEX increased the expression of
CRISPLD2 at both 4 and 24 hours in the experiments by Masuno,
et al. Consistent with the results of Masuno, et al, KLF15 was among
the top differentially expressed genes that we identified. Another
microarray study of the ASM transcriptome by Misior et al
(GSE13168) focused on the overlap of GC and beta-agonist gene
responses [18]. Of most relevance to our work, CRISPLD2 had
significantly increased expression levels when ASM cells were
treated with fluticasone. Further, the effect of fluticasone on
CRISPLD2 expression was diminished when ASM were also
treated with IL1b and/or EGF pro-inflammatory cytokines
[Table 3]. This suggests that CRISPLD2 levels were increased by
both EGF and IL1b and is consistent with our result that IL1b
increased CRISPLD2 expression [Figures 3C and 3D].
While in vitro studies of the ASM response to GCs that use RNA-
Seq have not been published, a recent study used RNA-Seq to
investigate the effects of a 2-week course of oral prednisolone on
ASM gene expression in patients with mild asthma, using ASM
extracted via laser caption microdissection from bronchoscopy
samples [51]. Comparing samples from 6 patients assigned to GC
treatment vs. 6 patients assigned to placebo, this study found that
15 genes were significantly differentially expressed between
groups, and two of the 15 genes were also associated with airway
hyperresponsiveness. Of these 15 genes, only one was significant in
our study (i.e. SYNPO2, adjusted P-value 0.015) [Table S3]. Future
studies of the in vivo GC response of ASM may help clarify the
differences between in vitro and in vivo study results.
Our study has identified well-known and more novel GC
responsive genes, but it was also subject to limitations. We used cell
lines from four white male subjects, and based on both RNA-Seq
and qRT-PCR results, there was significant variability in gene
expression levels among subjects. For example, the qRT-PCR data
in Figure 2 suggests that there is an inverse correlation between
levels of CRISPLD2 and C13orf15. That is, DEX seemed to induce
greater levels CRISPLD2 in cells that had lower levels of C13orf15.
Because the cell lines used were derived from ‘‘an outbred human
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complexity of the pathophysiology of asthma. Future studies with a
larger number of individuals and individuals of diverse gender and
racial/ethnic backgrounds may shed light on individualized
profiles of GC response, including identifying individuals who
are GC insensitive, and increase our understanding of how the
expression of various genes relates to each other. Our RNA-Seq
analyses were limited to the hg19 RefSeq annotation files
downloaded from Illumina’s iGenomes project. Thus, we did
not characterize the expression long-non-coding RNA or mRNA
transcript isoforms that were not part of the reference file used. We
opted for use of a well-annotated reference file for our
investigation of the ASM transcriptome to reduce the number of
false-positive results that we may have selected for follow-up.
Future studies with more comprehensive annotation files and a
greater number of individuals and/or greater sequencing depth
will yield additional insight into the ASM transcriptome.
While ASM is a target tissue in the GC treatment of asthma, our
ASM samples were not from asthma patients. Although the study
by Masuno et al found that there was general concordance
between response to DEX in 16 genes among four control ASM
cell lines and those of two asthma patients [17], there are likely
some differences in the GC response between asthma patients and
individuals without asthma. Further studies that include ASM
from asthma patients may help clarify such differences. Finally, it
is known that the response to GCs changes in time. For example,
the Masuno et al study compared the ASM GC response at both 4
and 24 hours, and it found that while some genes had consistent
changes at both time points, others had varied ones [17]. We
selected an 18-hour DEX treatment period partly because the
study by Masuno et al suggested that the set of genes regulated by
the GR expands greatly between 4 and 24 hours. Future studies
that evaluate the GC response over time would further define how
GCs alter the ASM transcriptome.
In summary, we identified 316 GC responsive genes in primary
ASM cell lines. The CRISPLD2 gene was selected for functional
studies based on having SNPs that were nominally associated with
ICS resistance and bronchodilator response, as well as having
published studies relating it to lung development and endotoxin
response. Based on results of in vitro experiments, CRISPLD2 was
found to be a modulator of IL1b response in ASM cells. Our
findings identified CRISPLD2 as a novel asthma pharmacogenetics
candidate gene and provide transcriptome data to further explore
the anti-inflammatory effects of GCs in the ASM.
Materials and Methods
Ethics Statement
Lung tissue was obtained from the National Disease Resource
Interchange (NDRI) and its use approved by the University of
Pennsylvania Institutional Review Board; use of the cells does not
constitute human research. Approval of the GWAS studies was
issued by the Partners Healthcare, Inc. Partners Human Research
Committee, which ensured that all procedures followed were in
accordance with the ethical standards of the responsible committee
on human experimentation, including obtaining written informed
consent for all study participants.
ASM Cell Culture and GC Treatment for RNA-Seq
Experiment
Primary ASM cells were isolated from four white aborted lung
transplant donors with no chronic illness. ASM cell cultivation and
characterization were described previously [52,53]. Passages 4 to 7
ASM cells maintained in Ham’s F12 medium supplemented with
10% FBS were used in all experiments. For the RNA-Seq and
qRT-PCR validation experiments, cells from each donor were
treated with 1 mM DEX (Sigma-Aldrich, St. Louis, MO) or
control vehicle for 18 h. For other experiments, cells were treated
with 100 nM DEX for 24 or 48 h.
RNA-Seq Library Construction and Sequencing
Total RNA was extracted from control and DEX-treated ASM
cells using the miRNAeasy mini kit (Qiagen Sciences, Inc.,
Germantown, MD). Approximately 1 mg of RNA from each
sample was used to generate RNA-Seq cDNA libraries for
sequencing using the TruSeq RNA Sample Prep Kit v2 (Illumina,
Inc., San Diego, CA). Sample preparation followed the manufac-
turer’s protocol with a workflow that included isolation of poly-
adenylated RNA molecules using poly-T oligo-attached magnetic
beads, enzymatic RNA fragmentation, cDNA synthesis, ligation of
bar-coded adapters, and PCR amplification. Ambion External
RNA Controls Consortium (ERCC) RNA Spike-In Control Mix 1
(Life Technologies Corporation, Carlsbad, CA) was added to the
samples. The amplified cDNA fragments were analyzed using the
2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA) to
determine fragment quality and size. Library concentrations were
determined by Qubit Fluorometric Quantitiation (Life Technol-
ogies Corporation, Carlsbad, CA). Sequencing of 75 bp paired-
end reads was performed with an Illumina HiSeq 2000 instrument
at the Partners HealthCare Center for Personalized Genetic
Medicine (Boston, MA).
RNA-Seq Data Analysis
Preliminary processing of raw reads was performed using
Casava 1.8 (Illumina, Inc., San Diego, CA). Subsequently, Taffeta
scripts (https://github.com/blancahimes/taffeta) were used to
analyze RNA-Seq data, which included use of FastQC [54]
(v.0.10.0) to obtain overall QC metrics. Based on having sequence
bias in the initial 12 bases on the 59 end of reads, the first 12 bases
of all reads were trimmed with the FASTX Toolkit (v.0.0.13) [55].
FastQC reports for each sample revealed that each was
successfully sequenced. Trimmed reads for each sample were
aligned to the reference hg19 genome and known ERCC
transcripts using TopHat [56] (v.2.0.4), while constraining
mapped reads to be within reference hg19 or ERCC transcripts.
Additional QC parameters were obtained to assess whether reads
were appropriately mapped. Bamtools [57] was used to the
number of mapped reads, including junction spanning reads. The
Picard Tools (http://picard.sourceforge.net) RnaSeqMetrics func-
tion was used to compute the number of bases assigned to various
classes of RNA, according to the hg19 refFlat file available as a
UCSC Genome Table. For each sample, Cufflinks [21] (v.2.0.2)
was used to quantify ERCC Spike-In and hg19 transcripts based
on reads that mapped to the provided hg19 and ERCC reference
files. For three samples that contained ERCC Spike-Ins, we
created dose response curves (i.e. plots of ERCC transcript FPKM
vs. ERCC transcript molecules) following the manufacturer’s
protocol [58]. Ideally, the slope and R
2 would equal 1.0. For our
samples (Dex.2, Control.4, Dex.4), the slope (R
2) values were 0.90
(0.90), 0.92 (0.84), 0.82 (0.86), respectively. Raw read plots were
created by displaying bigwig files for each sample in the UCSC
Genome Browser.
Differential expression of genes and transcripts in samples
treated with DEX vs. untreated samples was obtained using
Cuffdiff [21] (v.2.0.2) with the quantified transcripts computed by
Cufflinks (v.2.0.2), while applying bias correction. The CummeR-
bund [59] R package (v.0.1.3) was used to measure significance of
differentially expressed genes and create plots of the results. As a
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housekeeping genes (i.e., B2M, GABARAP, GAPDH, RPL19) were
obtained. Each had high FPKM values that did not differ
significantly by treatment status [Figure S11]. The NIH Database
for Annotation, Visualization and Integrated Discovery (DAVID)
was used to perform gene functional annotation clustering using
Homo Sapiens as background, and default options and annotation
categories (Disease: OMIM_DISEASE; Functional Categories:
COG_ONTOLOGY, SP_PIR_KEYWORDS, UP_SEQ_FEA-
TURE; Gene_Ontology: GOTERM_BP_FAT, GO-
TERM_CC_FAT, GOTERM_MF_FAT; Pathway: BBID, BIO-
CARTA, KEGG_PATHWAY; Protein_Domains: INTERPRO,
PIR_SUPERFAMILY, SMART) [28]. The RNA-Seq data is
available at the Gene Expression Omnibus Web site (http://www.
ncbi.nlm.nih.gov/geo/) under accession GSE52778.
Genome-wide Association Studies
Two GWAS of asthma-related traits that may be related to
ASM GC response were selected to measure association of SNPs
in/near top differentially expressed genes identified by RNA-Seq:
1) A GWAS of inhaled corticosteroid (ICS) response was
conducted in 723 non-Hispanic white asthmatics from the
following drug clinical trials: Childhood Asthma Management
Program (CAMP) [60], Leukotriene Modifier or Corticoste-
roid Salmeterol study (LOCCS) [61], and subsets of trials
within the Childhood Asthma Research and Education
(CARE) network [62], and the Asthma Clinical Research
Network (ACRN) [63] participating in the NHLBI SNP
Health Association Resource (SHARe) Asthma Resource
project (SHARP). ICS response was quantified as the percent
change in pre-BD FEV1 following 4–8 weeks of ICS therapy
[i.e. (onICSpreFEV1 – offICSpreFEV1)/offICSpreFEV1)].
Association of imputed SNPs (based on the June 2010 release
of the 1000 Genome Project reference) with ICS response was
measured using a linear regression model using PLINK [64].
2) Previously, a GWAS of bronchodilator response was con-
ducted in 1,644 non-Hispanic white asthmatics from drug
clinical trials [30]. Briefly, bronchodilator response was
quantified as the percent change in FEV1 in response to
administration of a b2-agonist bronchodilator (BD) [i.e. (post-
BD FEV1 – pre-BD FEV1)/pre-BD FEV1], and association of
single nucleotide polymorphisms (SNPs) with bronchodilator
response was measured using a linear regression model, while
adjusting for age, sex, and height. Results for 4,571,615
imputed SNPs (based on the June 2010 release of the 1000
Genome Project reference) were available.
Originally computed hg18 coordinates were converted to those
of the hg19 human genome assembly using the liftOver tool of the
UCSC genome browser. Variant names were converted to those
of the dbSNP build 138.
Publicly Available GC-treated ASM Microarray Expression
Data Analysis
Datasets from two publicly available gene expression micro-
array studies that measured the effect of GCs on human ASM cells
using in vitro models were obtained from the Gene Expression
Omnibus (GEO): GSE34313 and GSE13168. Raw signals of the
GSE34313 experiment, which used four replicates of a single ASM
cell line to investigate the effects of DEX at 4 and 24 hours using
the Agilent-014850 Whole Human Genome Microarray 4x44K
platform [17], were preprocessed with background correction and
quantile normalization using the limma R package [65]. The
GSE13168 dataset consisted of ASM cell cultures extracted from
four donor tracheas that were stimulated with a GC (fluticasone)
or a protein kinase A inhibitor as well as pro-inflammatory agents
(i.e. EGF and/or IL1b) or control and used the Affymetrix U133A
platform to measure gene expression changes [18]. Its raw signal
intensities were preprocessed with RMA as implemented in the
affy R package [66]. For both datasets, gene-based differential
expression analysis was conducted using the limma R package by
averaging probe intensities for individual genes [65].
Cell culture, Chemical Treatment and siRNA Transfection
ASM cells were maintained in Ham’s F12 medium supplemented
with 24 mM HEPES, 1.7 mM CaCl2, 12 Mm NaOH and 10% FBS.
For chemical treatment,cells grown in the above medium were washed
with PBS and switched to the serum deprivation medium. A549
human lung epithelial cells were maintained in high-glucose DMEM
medium containing 10% FBS. For chemical treatment, A549 cells
were washed and switched to DMEM/F12(1:1) medium supplement-
ed with 3% dialyzed FBS. 100 nM DEX (Sigma-Aldrich Corporation,
S t .L o u i s ,M O )o r5n g / m LI L 1 b (Invitrogen, Life Technologies,
Grand Island, NY) was then added to the medium. Transfection of
CRISPLD2 and non-targeting siRNA (siRNA universal non-targeting
control 1, Sigma-Aldrich Corporation, St. Louis, MO) was performed
using DharmaFECT 1 reagent according to the recommended
protocol from the manufacturer (Thermo Scientific, Lafayette, CO).
The final concentration of siRNA was 25 nM; siRNA sequences for
CRSIPLD2 knockdown were 59-GAACCAACAUCUAUGCAG-
A(dT)(dT)-39 and 59-UCUGCAUAGAUCUUGGUUC(dT)(dT)-39.
Quantitative Real-Time PCR (qRT-PCR) Analysis
Total RNA was isolated from cells by using QIAshredder and
RNeasy kits (Qiagen Sciences, Inc., Germantown, MD). Oli-
go(dT)-primed cDNA was prepared from 50 ng of total RNA by
using SuperScript III First-strand Synthesis System (Invitrogen,
Life Technologies, Grand Island, NY). qRT-PCR was set up in the
presence of 0.5 mM primers by using QuantiTect SYBR Green
PCR kit (Qiagen Sciences, Inc., Germantown, MD). qRT-PCR
was performed on an StepOne Plus real time PCR machine
(Applied Biosystems, Life Technologies, Grand Island, NY). b-
actin was used as an internal control for data normalization. Each
sample was measured in triplicate.
Immunoblot Analysis
Cells were washed with PBS and lysed in NP-40 lysing buffer
(50 mM Tris-HCl pH 7.5, 150 mM NaCl2, 0.5% Nonidet P-40)
containing protease inhibitor cocktail (Roche, Genentech, Inc.,
South San Francisco, CA). For the secreted CRISPLD2 protein
analysis, the medium was concentrated using Ultra-15 10 K
Centrifugal Filter Devices (Merck Millipore, Tullagreen, IRL).
Protein samples were separated on NuPAGE 4–12% Bis-Tris gels
(Invitrogen, Life Technologies, Grand Island, NY) and transferred
to PVDF membranes (Bio-Rad, Life Science Research, Hercules,
CA). Immunoblot signals were developed using SuperSignal West
Pico Chemiluminescent Substrates (Pierce Biotechnology, Inc.,
Rockford, IL). Primary antibodies used in the study included
rabbit polyclonal CRISPLD2 antibody (Abcam, Cambridge, MA)
and mouse monoclonal b-actin antibody (Santa Cruz Biotechnol-
ogy, Inc., Dallas, TX). Relative sample intensities were computed
with scanned and quantified immunoblot data obtained using
Image J software [67]. Each Western blot experiment was
performed 3 times; representative image results are shown.
Semi-quantitative results are reported as the mean +/2 SE.
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Figure S1 Estimated read coverage across transcripts
for each sample. Position and coverage are normalized by
adjusting for transcript lengths and total number of reads mapped
per sample.
(PNG)
Figure S2 Confirmation of qRT-PCR results supporting
RNA-Seq findings in the ASM cell line that was not used
for validation in Figure 1B or Figure 2. The mRNA levels of
the indicated genes were measured by qRT-PCR and the folds of
change induced by DEX were calculated for a single replicate.
(TIFF)
Figure S3 Association of SNPs near CRISPLD2 with A)
bronchodilator response and B) ICS resistance. The x-
axes denote position along Chromosome 16 according to the hg18
genome build. The y-axes denote –Log10(P) corresponding to
1000GP imputed data P-values. LD between the SNP with the
lowest P-values (chr16:83425008 and chr16:83522091) to each
SNP in the plot is denoted in colors and was computed according
to 1000GP June 2010 CEU data. Plot was created using
LocusZoom [68].
(TIFF)
Figure S4 Time and dose dependent effects of DEX on
CRISPLD2 expression. A) ASM cells were treated with
100 nM DEX for 24 and 48 h. B) ASM cells were treated with
DEX at indicated concentrations for 24 h. CRISPLD2 protein
was measured by immune-blotting.
(TIFF)
Figure S5 DEX induced expression change of CRISPLD2
in A549 pulmonary epithelial cells. A) Basal mRNA level of
CRISPLD2 in A549 and ASM cells. B) A549 cells were treated
with 100 nM DEX for 24 h and CRISPLD2 mRNA levels were
measured by qRT-PCR. Relative values of gene expression
shown. Experiment was performed in triplicate using cells from
a single donor. ** P,0.005, * P,0.05 (t test).
(TIFF)
Figure S6 CRISPLD2 regulates IL8 expression. ASM cells
were transfected with CRISPLD2-specific siRNA or non-targeting
(NT) siRNA, and 72 h later cell were treated with 5 ng/mL IL1b
for 24 h. IL8 mRNA expression was determined by qRT-PCR.
Normalized mRNA levels shown. All measurements were
performed in triplicate samples. * P,0.05 (t test).
(TIFF)
Figure S7 Effect of CRISPLD2 knockdown on GR target
gene expression. ASM cells were first transfected with
CRISPLD2-specific or NT siRNA and then stimulated with
100 nM DEX for 24 h. Induced expression (DEX treatment vs.
control) of three GR target genes was determined by qRT-PCR.
None of the target genes were found to be differentially expressed
(i.e. all had t-test P.0.05).
(TIFF)
Figure S8 Raw RNA-Seq read plots for four ASM cell
lines treated with DEX (red) or left untreated (blue)
along the human (hg19) chromosome 16 region contain-
ing CRISPLD2. Reads mapped to each exon of the RefSeq
version of CRISPLD2. An increased number of mapped reads is
observed in each sample after DEX treatment vs. when left
untreated. Shown below the RefSeq gene track are ENCODE
ChIP-Seq tracks: four are for sites found to bind the GR (official
gene name NR3C1) in A549 pulmonary epithelial cells at various
dosages of DEX (100 nM 50 nM, 5 nM, 500 pM) [12], and below
these are Transcription Factor ChIP-Seq V4 results for GR,
CEBPB, and CEBPD. Darker vertical lines represent binding sites
with higher scores (i.e. detected more strongly).
(TIFF)
Figure S9 RNA-Seq results from four ASM cell lines
treated with DEX expressed as FPKM for CEBPB and
CEBPD by condition status (i.e. DEX vs. untreated) show
the presence of both genes. DEX treatment did not
significantly change the expression levels of CEBPB but did
change the expression levels of CEBPD (Q-value 4.8E-04, Ln of
fold-change 1.47).
(TIFF)
Figure S10 Region of CRISPLD2 where SNPs were most
strongly associated with bronchodilator response (BDR)
along with GR- and CEBPB-binding sites identified by
ENCODE Transcription Factor ChIP-Seq V4 results. The
x-axis denotes position along Chromosome 16 in hg19 genome
build coordinates. The vertical axis of the BDR GWAS Results
denotes –Log10(P-values), and the horizontal line at 1.3 represents
a nominal significance threshold of P-value=0.05. Shown below
the RefSeq gene track are ENCODE ChIP-Seq tracks for sites
found to bind the GR (official gene name NR3C1) in A549
pulmonary epithelial cells at various dosages of DEX (100 nM
50 nM, 5 nM, 500 pM) [12], and below these are Transcription
Factor ChIP-Seq V4 results for GR, CEBPB, and CEBPD. Darker
ChIP-Seq regions represent binding sites with higher scores (i.e.
detected more strongly).
(TIFF)
Figure S11 RNA-Seq results from four ASM cell lines
treated with DEX expressed as FPKM for four house-
keeping genes (i.e. B2M, GABARAP, GAPDH, RPL19)b y
condition status (i.e. DEX vs. untreated) show high
levels of expression for each gene that did not signifi-
cantly differ with DEX treatment.
(TIFF)
Table S1 Number of various read types per sample in millions.
Values in parenthesis for unmapped and mapped reads corre-
spond to percentages of total reads per sample, while values in
parenthesis for all other entries correspond to percentages of total
mapped reads per sample.
(DOCX)
Table S2 Percentage of mapped bases according to hg19
reference refFlat file base type.
(DOCX)
Table S3 Significantly differentially expressed genes.
(DOCX)
Table S4 Functional annotation clusters obtained with the NIH
DAVID tool using differentially expressed genes in Table S3.
Clusters with enrichment scores .1.5 are shown. Individual P-
values listed correspond to EASE Scores, or modified Fisher Exact
P-Values computed by DAVID.
(DOCX)
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